Avanti Polar Lipids part of Croda International Plc

10:30 AM - 10:45 AM (PDT), Wednesday, June 15, 2022

As the Lipid Technology segment of Croda Pharma, part of the Life Science sector of Croda Inc., Avanti is primarily focused on developing innovative lipid-based products of unparalleled purity to address specific medical challenges that are not resolved by current technology or drug products. For over 30 years, Avanti Polar Lipids has supported and been involved in gene therapy research. Through our manufacturing of high-purity lipids for nucleic acid delivery, we have facilitated clinical development of novel vaccines and therapeutics. We will summarize the path that put Avanti at the forefront of the Race to Beat COVID-19.

Ticker:
CRDA
Exchange:
LSE
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Alabama
Company HQ Country:
United States
Year Founded:
1967
Main Therapeutic Focus:
Lead Product in Development:
Products for LNP Technology; Nucleic Acid Delivery
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided